AVET Amoxyclav 500 mg Tablets

Riik: Austraalia

keel: inglise

Allikas: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Toimeaine:

AMOXICILLIN TRIHYDRATE; POTASSIUM CLAVULANATE

Saadav alates:

AVET HEALTH LIMITED

Ravimvorm:

ORAL TABLET

Koostis:

AMOXICILLIN TRIHYDRATE ACTIVE Active 400.0 mg; POTASSIUM CLAVULANATE ANTIBIOTIC Active 100.0 mg

Ühikuid pakis:

100 Tablets

Klass:

VM - Veterinary Medicine

Terapeutiline ala:

ANTIBIOTIC & RELATED

Toote kokkuvõte:

Poison schedule: 4; Withholding period: MEAT: CALVES - DO NOT USE less than 4 da ys before slaughter for human consumptio n. Any variation by the prescribing vet erinarian to the approved dose, frequenc y, duration, route, disease or target sp ecies may result in the need to extend t he approved withholding period. EXPOR T SLAUGHTER INTERVAL (ESI): An ESI has n ot been established for this product. N ote - observing the meat withholding per iod may not be sufficient to mitigate po tential risks to export trade. Trade adv ice should be sought from Avet Health LT D on 1800 28 38 28 before using this pro duct.; Host/pest details: CALF: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]; DOG: [ANTIBIOTICS - ORAL, PARENTERAL, BACTERIAL INFECTION]

Volitamisolek:

Registered

Loa andmise kuupäev:

2023-09-13

Infovoldik

Product Name:
APVMA Approval No:
AVET Amoxyclav 500 mg Tablets
93475/139283
Label Name:
AVET Amoxyclav 500 mg Tablets
Signal Headings:
PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each tablet contains 400 mg AMOXYCILLIN as AMOXYCILLIN TRIHYDRATE and
100 mg
CLAVULANIC ACID as DILUTED POTASSIUM CLAVULANATE.
Claims:
For use by or under direction of a veterinarian. For the treatment of
bacterial infections
sensitive to clavulanic acid and amoxicyllin in calves and dogs.
AVET Amoxyclav 500 mg Tablets have a notably broad spectrum of
bactericidal activity
against bacteria commonly found in calves and dogs and are indicated
for the oral
treatment of bacterial infections caused by susceptible organisms.
These include enteritis,
respiratory tract infections and skin infections in dogs.
PRODUCT SUMMARY
• Dual action of clavulanic acid and amoxycillin.
• Extended spectrum of activity - clavulanate extends the spectrum
of amoxycillin by
making it active against resistant
(B-lactamase producing) strains of Staphylococcus spp., E. coli and
Salmonella spp., as
well as adding Klebsiella spp.
to the list of susceptible organisms.
• Rapid bactericidal action - increases the likelihood of a rapid
clinical cure.
• Excellent absorption and penetration.
• Easy to administer.
• Convenient twice daily dosage.
• Absorption not significantly affected by food.
MODE OF ACTION
Resistance to many antibiotics is caused by B-lactamase enzymes which
destroy the
antibiotic before it can act on the bacteria. The clavulanate in AVET
Amoxyclav counteracts
this defence mechanism by inactivating the B-lactamases, thus
rendering the organisms
sensitive to amoxycillin's rapid bactericidal effect at concentrations
readily attainable in the
body.
In vitro AVET Amoxyclav is active against a wide range of clinically
important bacteria,
including:
Gram - positive
Staphylococcus spp (including B-lactamase producing strains);
Corynebacterium spp.; Streptococcus spp. RLP APPROVED
Gram -